YARDLEY, Penn. – March 31, 2022 – Herspiegel, a leading life science consulting firm specializing in commercialization strategy and execution, announced today that seasoned biopharma consultant, Swathi Rangan, has been promoted to Principal at the company. In her new role, Ms. Rangan leads strategy and implementation across commercial projects with a heavy specialty in patient services design, brand strategy, and launch readiness.
“We are thrilled to support Swathi’s continued development at Herspiegel. Swathi consistently brings value to our biopharma clients by clearly articulating business challenges, designing strategic solutions, and efficiently leading implementation to help clients tackle critical business issues,” said Beth Schurman, Partner and Chief Operating Officer at Herspiegel. “Client teams proactively share how important she has become as a thought partner and leader on the Herspiegel executive team to ensure timely and impactful execution.”
Ms. Rangan assumes her new role at Herspiegel as the firm expands its client offerings and penetrates new geographic markets after receiving a growth investment from DFW Capital Partners in December 2021. Biopharma clients, in particular, are challenged with progressively complex commercial landscapes which create increased demand for Herspiegel’s industry-leading experience and strategic services.
Ms. Rangan expressed her anticipation and goals for the role, “I am excited for the new opportunities that come with this role of Principal, especially as the Herspiegel team continues to grow and evolve. I intend to continue supporting clients solve complex business challenges and look forward to collaborating more on executing our own firm vision.” said Ms. Rangan.
Ms. Rangan previously held the position of Senior Manager at Herspiegel. She joined the company as Associate Consultant, bringing several years of experience within the industry, in marketing as well as the lab, as a biomedical and pharmaceutical research analyst. She possesses a Master of Business Administration degree in pharmaceutical management and marketing from Rutgers Business School, and a Master of Science degree in biomedical sciences with a concentration in pharmacological sciences from the University of Medicine and Dentistry of New Jersey.
